Novo’s Wegovy Pill Isn’t Just Beating Expectations — It’s Obliterating Them. Is the Beaten-Down Stock a Buy Now?
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn't be on any clearer display than in the competition between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) in the newly created GLP-1 weight-loss space. While Eli Lilly looks like the winner right now, Novo Nordisk's Wegovy pill is performing better than expected. That's important,…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
